JPS61236725A - Agent for suppressing cerebral edema - Google Patents

Agent for suppressing cerebral edema

Info

Publication number
JPS61236725A
JPS61236725A JP7769685A JP7769685A JPS61236725A JP S61236725 A JPS61236725 A JP S61236725A JP 7769685 A JP7769685 A JP 7769685A JP 7769685 A JP7769685 A JP 7769685A JP S61236725 A JPS61236725 A JP S61236725A
Authority
JP
Japan
Prior art keywords
agent
quercitrin
cerebral edema
cerebral
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP7769685A
Other languages
Japanese (ja)
Other versions
JPH0615473B2 (en
Inventor
Junji Tanaka
淳二 田中
Hisaya Kogure
小暮 久也
Akimasa Nishida
西田 暁正
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Priority to JP7769685A priority Critical patent/JPH0615473B2/en
Publication of JPS61236725A publication Critical patent/JPS61236725A/en
Publication of JPH0615473B2 publication Critical patent/JPH0615473B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To provide the titled suppressing agent containing quercitrin as an active component. CONSTITUTION:The objective agent for suppressing cerebral edema is obtained by using quercitrin of formula as an active component. The agent is effective for the remedy and prevention of cerebral edema accompanying to ischemic cerebrovascular disorder such as cerebral infraction, cerebral hemorrhage, etc. It is administered in the form of tablet, capsule, powder, granule, syrup, injection, etc., at a does of 10mg-10g daily, especially 200mg-5g daily by oral administration and 10mg-2g, especially 100mg-1.5mg daily by intravenous injection in several divided doses.

Description

【発明の詳細な説明】 &Jヱと」迫 本発明は、新規な脳浮腫抑制剤を提供することを目的と
する。
DETAILED DESCRIPTION OF THE INVENTION An object of the present invention is to provide a novel cerebral edema inhibitor.

従1m術 脳浮腫に対する薬剤として、現在グリセロールあるいは
マンニトールがよく使われている。しかし、これらは電
解質バランスの障害(高ナトリウム血症)や腎障害を惹
起することが知られており未だ満足しうる薬剤とは言え
ない。
Currently, glycerol or mannitol is commonly used as a drug for cerebral edema following surgery. However, these drugs are known to cause disturbances in electrolyte balance (hypernatremia) and renal damage, and are not yet satisfactory drugs.

&1五璽輩 本発明は、ケルシトリンを有効成分とする脳浮腫抑制剤
に関するものである。ケルシトリンは次の構造式を有す
るフラボノイドの一種である公知化合物である。
The present invention relates to a cerebral edema inhibitor containing quercitrin as an active ingredient. Quercitrin is a known compound that is a type of flavonoid and has the following structural formula.

本発明者はケルシトリンのラットの実験的脳虚血モデル
に対する効果を検討したところ有意に優れた効果を見出
し本発明を完成した。次に実験例を挙げて説明する。
The present inventor investigated the effect of quercitrin on an experimental cerebral ischemia model in rats and found a significantly superior effect, thereby completing the present invention. Next, an explanation will be given using an experimental example.

実験例:脳浮腫生成に対するケルシトリンの効果WjS
tarラット(体重230〜280g、雄)の両側椎骨
動脈の血流を遮断し、さらに両側椎骨動脈の血流を60
分間遮断した。その後60分間血流を再開通させてラッ
トの実験的脳虚血モデルを作成した(W、A、Pu1s
inelli、et al、、5troke、す、26
7(1973)参照)。
Experimental example: Effect of quercitrin on brain edema generation WjS
The blood flow in both vertebral arteries of tar rats (weight 230-280 g, male) was blocked, and the blood flow in both vertebral arteries was further reduced for 60 min.
It was shut off for a minute. Thereafter, blood flow was recanalized for 60 minutes to create an experimental cerebral ischemia model in rats (W, A, Pu1s
inelli,et al,,5stroke,su,26
7 (1973)).

本モデルに対して、血流遮断5分前にケルシトリン5 
m g / k gを生理食塩液態濁液として大腿静脈
より注入した。対照群には生理食塩液のみを注入した。
In this model, 5 minutes of quercitrin was administered 5 minutes before blood flow was blocked.
mg/kg was injected into the femoral vein as a physiological saline suspension. The control group received only physiological saline.

さらに無処置動物も対照とした。In addition, untreated animals also served as controls.

−・ノリ方法(J 、 Neurochem、 。-・Nori method (J, Neurochem,.

21.、=、=r(1973))に従い液体窒素で脳を
凍結後摘出し、その前頭部的100mgを秤量後凍結乾
燥し、湿重量と乾燥重量の差から求め、これを指標とし
て効果を検討した。結果を表に示す。
21. ,=,=r (1973)), the brain was frozen with liquid nitrogen, removed, and 100 mg of the frontal portion was weighed and freeze-dried. It was determined from the difference between wet weight and dry weight, and the effect was examined using this as an index. did. The results are shown in the table.

この結果から、ケルシトリン投与群における脳水分含量
は生理食塩液投与群におけるそれよりも有意に(P <
 0.05)低く、ケルシトリンに脳浮腫抑制作用があ
ることが明らかとなった。
From this result, the brain water content in the quercitrin-administered group was significantly higher than that in the physiological saline-administered group (P <
0.05), indicating that quercitrin has a cerebral edema suppressing effect.

本発明の薬剤は、脳梗塞、脳出血などの虚血性脳血管障
害に伴なう脳浮腫の治療および予防に有効である。
The drug of the present invention is effective in treating and preventing cerebral edema associated with ischemic cerebrovascular disorders such as cerebral infarction and cerebral hemorrhage.

ケルシトリンは、適当な副成分(賦形剤、結合剤、崩壊
剤、溶解剤等)と慣用の製剤技術で製剤化することがで
きる0例えば、錠剤、カプセル剤、散剤、顆粒剤、シロ
ップ剤、注射剤等の剤形を挙げることができ、経口また
は注射により投与するのが適当である。製剤の一例を次
に示す。
Quercitrin can be formulated with appropriate accessory ingredients (excipients, binders, disintegrants, solubilizers, etc.) using conventional formulation techniques.For example, tablets, capsules, powders, granules, syrups, etc. Examples include dosage forms such as injections, which are suitably administered orally or by injection. An example of the formulation is shown below.

錠剤 ケルシトリン         50 tsgカルボキ
シメチルセルロース  25 tagでんぷん    
        5■g結晶セルロース       
 40 tagステアリン酸マグネシウム    2 
tag投与量としては、経口では成人−日当り10mg
乃至10g、特に200mg乃至5g、静脈内注射等の
注射では10mg乃至2g、特に100mg乃至1.5
gが適当であり、数回に分けて投与するのが普通であっ
て、症状や患者の状態等に応じて適宜増減する。
tablet quercitrin 50 tsg carboxymethyl cellulose 25 tag starch
5g crystalline cellulose
40 tag Magnesium Stearate 2
The tag dosage is 10 mg per day for adults.
10g to 10g, especially 200mg to 5g, 10mg to 2g for injections such as intravenous injection, especially 100mg to 1.5g.
It is appropriate to administer the dose in several doses, and the dose may be increased or decreased as appropriate depending on the symptoms, patient's condition, etc.

ケルシトリンの毒性は医薬としての使用に支障のない範
囲であり、例えば、マウス腹腔内注射におけるLDso
は200mg/kgテある(Registry of 
ToxicEffects of Chemical 
5ubstances(1981−1982Editi
on) U、S、Department of Hea
lth and HumanServices) 。
The toxicity of quercitrin is within a range that does not interfere with its use as a medicine.
is 200mg/kg (Registry of
Toxic Effects of Chemical
5ubstances (1981-1982Editi
on) U, S, Department of Hea
lth and Human Services).

Claims (1)

【特許請求の範囲】[Claims] ケルシトリンを有効成分とする脳浮腫抑制剤Brain edema inhibitor containing quercitrin as an active ingredient
JP7769685A 1985-04-12 1985-04-12 Brain edema inhibitor Expired - Lifetime JPH0615473B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP7769685A JPH0615473B2 (en) 1985-04-12 1985-04-12 Brain edema inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7769685A JPH0615473B2 (en) 1985-04-12 1985-04-12 Brain edema inhibitor

Publications (2)

Publication Number Publication Date
JPS61236725A true JPS61236725A (en) 1986-10-22
JPH0615473B2 JPH0615473B2 (en) 1994-03-02

Family

ID=13641052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7769685A Expired - Lifetime JPH0615473B2 (en) 1985-04-12 1985-04-12 Brain edema inhibitor

Country Status (1)

Country Link
JP (1) JPH0615473B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030013177A (en) * 2001-08-07 2003-02-14 황귀서 A pharmaceutical composition containing quercitin as effective component
KR100989093B1 (en) 2008-01-18 2010-10-25 한화제약주식회사 Composition Comprising the Extracts of Branch of Lindera obtusiloba for Prevention and Treatment of Cardiovascular Diseases
WO2024101208A1 (en) * 2022-11-07 2024-05-16 サントリーホールディングス株式会社 Composition for suppressing and/or improving decreased cerebral blood flow, containing quercetin and/or glycoside thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030013177A (en) * 2001-08-07 2003-02-14 황귀서 A pharmaceutical composition containing quercitin as effective component
KR100989093B1 (en) 2008-01-18 2010-10-25 한화제약주식회사 Composition Comprising the Extracts of Branch of Lindera obtusiloba for Prevention and Treatment of Cardiovascular Diseases
WO2024101208A1 (en) * 2022-11-07 2024-05-16 サントリーホールディングス株式会社 Composition for suppressing and/or improving decreased cerebral blood flow, containing quercetin and/or glycoside thereof

Also Published As

Publication number Publication date
JPH0615473B2 (en) 1994-03-02

Similar Documents

Publication Publication Date Title
RU2262933C2 (en) Aspirin-comprising medicinal compositions
US6191153B1 (en) Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity
KR950009094B1 (en) Pharmaceutical compositions containing pyridoxine derivatives for use in the prevention and treatment of hyperlipemia and atherosclerosis
JPH0729916B2 (en) Pharmaceutical composition having analgesic properties
JPH05194209A (en) Hemangioendothelial cell function improver
BE905198A (en) PHARMACEUTICAL PREPARATIONS WITH DILUSATING AND ANTI-ANOXIC ACTION.
Schulert et al. The physiologic disposition of phenylindanedione in man
JPS5938203B2 (en) A therapeutic agent for cerebral circulation disorders whose main ingredient is coenzyme Q.
AU666992B2 (en) Pharmaceutical composition for preventing or treating arteriosclerosis
JPS61236725A (en) Agent for suppressing cerebral edema
JPH06500537A (en) Use of arylhydroxyurea compounds for the treatment of atherosclerosis
JPH01221316A (en) Cerebral circulatory metabolism-improving agent
JPH01131113A (en) Remedy for encephalopathy
US3932652A (en) Antidepressant compositions
US6306901B1 (en) Agent for prophylaxis and therapy of diseases
JP5376785B2 (en) Pharmaceutical composition
JPS5938204B2 (en) Aplastic anemia treatment agent
EP0256629A2 (en) Tolrestat or a salt thereof as an immuno-stimulating agent
JPS63198630A (en) Lipid metabolism improver
US3658964A (en) 2-phenylacetylbenzoic acid in the treatment of inflammation
JPH01305033A (en) Circulation improving agent, circulation improving functional food and tasteful food
US3764679A (en) Iodinin as an anti-hypertensive agent
US4716177A (en) Tolrestat for inhibition of weight gain
JPH0445494B2 (en)
JPH0320221A (en) Hepatopathy therapeutic agent